Chester County News and Community Website
Are you looking for Chester County businesses that are traded on the Nasdaq Stock Market? Would you love adding a Chester County business to your investment portfolio or 401k? The process of building a properly diversified portfolio, which includes investments in local businesses, is an important personal financial strategy.
Here you will find news and updates from Chester County businesses that are listed on the Nasdaq Stock Market. There is a growing appetite for real, local business news about publicly traded companies. MyChesCo features local business news from around Chester County. Moreover, we provide in-depth articles about Chester County’s dynamic business and economic scene, including tips for small biz owners, marketing, management, startups, entrepreneurship, and more.
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has successfully completed enrollment in the Phase 3 SELVA clinical trial of QTORIN™ 3.9% rapamycin anhydrous gel, a potential breakthrough treatment for …
Palvella Therapeutics Announces Completion of Phase 3 SELVA Trial for QTORIN Rapamycin Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has launched a Phase 1a/1b clinical program to evaluate the safety and efficacy of ATI-052, an investigational bispecific anti-TSLP/IL-4R antibody that could …
Aclaris Therapeutics Begins Phase 1a/1b Trial for Investigational Bispecific Antibody ATI-052 Read More
EXTON, PA — Omega Flex, Inc. (NASDAQ: OFLX) announced that its Board of Directors declared a regular quarterly dividend of $0.34 per share, payable on July 10, 2025, to shareholders …
Omega Flex Declares Quarterly Dividend of $0.34 Per Share Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the issuance of U.S. patent No. 12,329,748 by the United States Patent and Trademark Office (USPTO), providing increased protection for its …
Palvella Therapeutics Secures New Patent for QTORIN™ Rapamycin Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received clearance from the U.S. Food and Drug Administration (FDA) to begin a Phase 2/3 pivotal confirmatory trial of OCU410ST, an innovative …
Ocugen Receives FDA Clearance for Phase 2/3 Trial of Genetic Therapy for Stargardt Disease Read More
MALVERN, PA & TROY, MI — Cantaloupe, Inc. (NASDAQ: CTLP) has entered into a definitive agreement to be acquired by 365 Retail Markets, LLC (“365”) in an all-cash transaction valued …
365 Retail Markets to Acquire Cantaloupe, Inc. in $848 Million All-Cash Deal Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced its participation in the 2025 BIO International Convention, held from June 16-19 at the Boston Convention & Exhibition Center. The biopharmaceutical company …
Ocugen to Showcase Gene Therapy Advancements at 2025 BIO International Convention Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has received the initial proceeds from a prestigious FDA Orphan Products Development grant to support its ongoing Phase 3 SELVA trial of …
Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin Read More
MALVERN, PA — TELA Bio, Inc. (NASDAQ: TELA) announced that its Board of Directors Compensation Committee approved an inducement grant for Jim Hagen, Senior Vice President – Strategic Commercial Operations. …
TELA Bio Welcomes Jim Hagen with Strategic Equity Grant Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has signed a binding term sheet with a prominent pharmaceutical and healthcare company in Korea, granting exclusive Korean rights to OCU400, its experimental …
Ocugen Secures Licensing Agreement for OCU400 in Korea Read More